title: MiR-130a-3p regulates cell migration and invasion via inhibition of Smad4 in gemcitabine resistant hepatoma cells.
abstract: BACKGROUND
  Emerging evidence demonstrates that microRNAs (miRNAs) play an important role in regulation of cell growth, invasion and metastasis through inhibiting the expression of their targets. It has been reported that miR-130a-3p controls cell growth, migration and invasion in a variety of cancer cells. However, it is unclear whether miR-130a-3p regulates epithelial-mesenchymal transition (EMT) in drug resistant cancer cells. Therefore, in the current study, we explore the role and molecular mechanisms of miR-130a-3p in gemcitabine resistant (GR) hepatocellular carcinoma (HCC) cells.
  
  
  METHODS
  The real-time RT-PCR was used to measure the miR-130a-3p expression in GR HCC cells compared with their parental cells. The wound healing assay was conducted to determine the cell migratory activity in GR HCC cells treated with miR-130a-3p mimics. The migration and invasion assays were also performed to explore the role of miR-130a-3p in GR HCC cells. Western blotting analysis was used to measure the expression of Smad4, E-cadherin, Vimentin, and MMP-2 in GR HCC cells after depletion of Smad4. The luciferase assay was conducted to validate whether Smad4 is a target of miR-130a-3p. The student t-test was used to analyze our data.
  
  
  RESULTS
  We found the down-regulation of miR-130a-3p in GR HCC cells. Moreover, we validate the Smad4 as a potential target of miR-130a-3p. Furthermore, overexpression of miR-130a-3p suppressed Smad4 expression, whereas inhibition of miR-130a-3p increased Smad4 expression. Consistently, overexpression of miR-130a-3p or down-regulation of Smad4 suppressed the cell detachment, attachment, migration, and invasion in GR HCC cells.
  
  
  CONCLUSIONS
  Our findings provide a molecular insight on understanding drug resistance in HCC cells. Therefore, activation of miR-130a-3p or inactivation of Smad4 could be a novel approach for the treatment of HCC.
authors.affiliation: Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
authors.forename: Yumei
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
authors.forename: Rui
authors.initials: R
authors.lastname: Wang
authors.affiliation: Department of Medical Oncology, PLA Cancer Center, Nanjing Bayi Hospital, Nanjing, Jiangsu, China.
authors.forename: Shukui
authors.initials: S
authors.lastname: Qin
authors.affiliation: Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Liu
authors.affiliation: Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
authors.forename: Fang
authors.initials: F
authors.lastname: Su
authors.affiliation: Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Yang
authors.affiliation: Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
authors.forename: Fuyou
authors.initials: F
authors.lastname: Zhao
authors.affiliation: Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
authors.forename: Zishu
authors.initials: Z
authors.lastname: Wang
authors.affiliation: Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China. qiongwu68@outlook.com.
authors.forename: Qiong
authors.initials: Q
authors.lastname: Wu
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D045744:Cell Line, Tumor; D002465:Cell Movement; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm; D058750:Epithelial-Mesenchymal Transition; D015972:Gene Expression Regulation, Neoplastic; D056945:Hep G2 Cells; D006801:Humans; D008113:Liver Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D035683:MicroRNAs / Q000235:genetics*; D009361:Neoplasm Invasiveness; D051901:Smad4 Protein / Q000235:genetics / Q000378:metabolism*; D000093542:Gemcitabine
chemical_list: C554019:MIRN130 microRNA, human; D035683:MicroRNAs; C497796:SMAD4 protein, human; D051901:Smad4 Protein; D003841:Deoxycytidine; D000093542:Gemcitabine
references.citation: Int J Clin Exp Pathol. 2015;8(1):384-93
references.pmid: 25755726
references.citation: Oncotarget. 2015 Mar 30;6(9):7000-10
references.pmid: 25760076
references.citation: PLoS One. 2015;10(6):e0128886
references.pmid: 26043084
references.citation: J Exp Clin Cancer Res. 2015;34:59
references.pmid: 26063204
references.citation: BMC Cancer. 2015;15:469
references.pmid: 26077733
references.citation: J Exp Clin Cancer Res. 2015;34:73
references.pmid: 26223867
references.citation: J Exp Clin Cancer Res. 2015;34:76
references.pmid: 26243299
references.citation: Prostate. 2015 Oct;75(14):1568-78
references.pmid: 26074357
references.citation: PLoS One. 2015;10(9):e0137706
references.pmid: 26352740
references.citation: Oncogene. 2015 Sep 24;34(39):5055-68
references.pmid: 25531314
references.citation: Oncotarget. 2015 Sep 22;6(28):25093-108
references.pmid: 26231037
references.citation: J Exp Clin Cancer Res. 2015;34:140
references.pmid: 26576645
references.citation: J Cancer Res Clin Oncol. 2016 Jan;142(1):177-85
references.pmid: 26206483
references.citation: Stem Cells. 2008 Jun;26(6):1425-35
references.pmid: 18403754
references.citation: Gynecol Oncol. 2008 Dec;111(3):478-86
references.pmid: 18823650
references.citation: Cancer Res. 2009 Mar 15;69(6):2400-7
references.pmid: 19276344
references.citation: Int J Biol Sci. 2010;6(1):1-8
references.pmid: 20087440
references.citation: Cancer Res. 2010 Jun 15;70(12):5184-93
references.pmid: 20501828
references.citation: Drug Resist Updat. 2010 Aug-Oct;13(4-5):109-18
references.pmid: 20692200
references.citation: Br J Cancer. 2010 Nov 9;103(10):1617-26
references.pmid: 20978511
references.citation: Head Neck. 2011 Jun;33(6):786-91
references.pmid: 21560177
references.citation: Neoplasia. 2011 Jul;13(7):590-600
references.pmid: 21750653
references.citation: Acta Biochim Biophys Sin (Shanghai). 2011 Aug;43(8):640-6
references.pmid: 21712254
references.citation: Cancer Lett. 2011 Nov 28;310(2):160-9
references.pmid: 21802841
references.citation: Cancer Prev Res (Phila). 2011 Oct;4(10):1698-709
references.pmid: 21836020
references.citation: N Engl J Med. 2011 Sep 22;365(12):1118-27
references.pmid: 21992124
references.citation: Blood. 2011 Dec 15;118(25):6649-59
references.pmid: 22028478
references.citation: Oncogene. 2012 Feb 2;31(5):634-42
references.pmid: 21706050
references.citation: J Biol Chem. 2012 Feb 17;287(8):5639-49
references.pmid: 22117060
references.citation: Oncol Rep. 2012 Aug;28(2):592-600
references.pmid: 22614869
references.citation: Biochem Biophys Res Commun. 2012 Aug 24;425(2):468-72
references.pmid: 22846564
references.citation: Curr Drug Targets. 2012 Dec;13(14):1750-6
references.pmid: 23140286
references.citation: Hepatology. 2013 Aug;58(2):629-41
references.pmid: 23471579
references.citation: Exp Biol Med (Maywood). 2013 Sep;238(9):1024-32
references.pmid: 23925649
references.citation: Acta Biochim Biophys Sin (Shanghai). 2013 Dec;45(12):995-1001
references.pmid: 24145606
references.citation: Oncotarget. 2013 Nov;4(11):1999-2009
references.pmid: 24158561
references.citation: Technol Cancer Res Treat. 2014 Feb;13(1):77-86
references.pmid: 23862748
references.citation: Gene. 2014 Apr 1;538(2):342-7
references.pmid: 24447717
references.citation: Mol Cancer. 2014;13:35
references.pmid: 24565101
references.citation: Asian Pac J Cancer Prev. 2014;15(3):1391-6
references.pmid: 24606471
references.citation: J Exp Clin Cancer Res. 2014;33:12
references.pmid: 24468065
references.citation: ACS Chem Biol. 2014 Mar 21;9(3):711-21
references.pmid: 24359019
references.citation: Br J Cancer. 2014 Apr 15;110(8):1958-67
references.pmid: 24642627
references.citation: Biochem Biophys Res Commun. 2014 Apr 25;447(1):210-5
references.pmid: 24704424
references.citation: PLoS One. 2014;9(5):e96228
references.pmid: 24788655
references.citation: Oncotarget. 2014 Jul 15;5(13):4959-71
references.pmid: 24970806
references.citation: Cancer Lett. 2014 Oct 1;352(2):245-52
references.pmid: 25034398
references.citation: J Biol Chem. 2014 Aug 22;289(34):23796-808
references.pmid: 25002578
references.citation: Int J Oncol. 2014 Oct;45(4):1537-46
references.pmid: 25096647
references.citation: Med Oncol. 2014 Oct;31(10):230
references.pmid: 25218269
references.citation: Curr Pharm Des. 2014;20(33):5348-53
references.pmid: 24479798
references.citation: Curr Pharm Des. 2014;20(33):5354-61
references.pmid: 24479808
references.citation: Mol Med Rep. 2015 Jan;11(1):677-81
references.pmid: 25333670
references.citation: Ann Surg Oncol. 2014 Dec;21 Suppl 4:S591-600
references.pmid: 24740829
references.citation: PLoS One. 2014;9(12):e115565
references.pmid: 25531114
references.citation: Asian Pac J Cancer Prev. 2014;15(23):10439-44
references.pmid: 25556489
references.citation: CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
references.pmid: 25559415
references.citation: Tumour Biol. 2015 Jan;36(1):111-9
references.pmid: 25464861
references.citation: CA Cancer J Clin. 2015 Mar;65(2):87-108
references.pmid: 25651787